It is disclosed a method which relates to the ex-vivo of synthesizing J-Factor and its therapeutic application. In-vivo mechanism involves the secretion of Growth Hormone (GH), and its binding to the GH receptor. During enzymatic interaction between GH and the receptor, at least one of its amino acid specifically L-arginine is changed to J-factor by the bond shifting action in the guanidino group of L-arginine. Finally the GH is broken down into its respective amino acid units within the cell, and the J-Factor starts to accumulate gradually. Thus accumulated J-factor stimulates the synthesis and secretion of autocrine-paracrine IGF-1. IGF-I induces changes in the cell which prevent aging signs. The method further relates to ex-vivo synthesis of J-factor which is responsible for the changes in the cell and its administration to humans and animal. In one of the preferred embodiment the ex-vivo synthesized J-factor is administrated to the patients and the changes in the patients was observed.